CD133 Promotes Adhesion to the Ovarian Cancer Metastatic Niche

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Cancer stem cells (CSCs) are implicated in ovarian cancer metastasis and chemoresistance.
• CD133 is a key marker for ovarian CSCs, associated with increased tumorigenicity and metastasis.
• The transcription factor ARID3B has been previously linked to increased PROM1 (CD133) expression in ovarian cancer cells.

Purpose of the Study:

• To elucidate the regulatory mechanism of CD133 expression by ARID3B.
• To investigate the role of ARID3B-mediated CD133 regulation in ovarian cancer growth and metastasis.
• To determine the functional significance of CD133 in ovarian cancer cell adhesion to the mesothelium.

Main Methods:

• Investigated ARID3B's direct regulation of PROM1 (CD133) expression in ovarian cancer cells.
• Utilized a xenograft mouse model to assess the impact of PROM1 knockdown on tumor growth in ARID3B-overexpressing cells.
• Examined the effect of PROM1 expression on ovarian cancer cell adhesion to peritoneal mesothelium in vitro and ex vivo.

Main Results:

• ARID3B directly regulates the expression of PROM1 (CD133).
• Knockdown of PROM1 in ARID3B-expressing ovarian cancer cells significantly increased survival in a mouse model, highlighting PROM1's role in tumor growth.
• PROM1 expression enhanced ovarian cancer cell adhesion to the mesothelium, suggesting a role in metastatic spread.

Conclusions:

• ARID3B directly controls CD133 expression in ovarian cancer.
• The ARID3B-CD133 axis is critical for ovarian tumor growth and survival.
• CD133 promotes ovarian cancer metastasis by increasing adhesion to the mesothelial niche.